Form 8-K - Current report:
SEC Accession No. 0001437749-24-035616
Filing Date
2024-11-18
Accepted
2024-11-18 16:16:22
Documents
15
Period of Report
2024-11-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.01: Changes in Control of Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20241115_8k.htm   iXBRL 8-K 33407
2 EXHIBIT 10.1 ex_749092.htm EX-10.1 140261
  Complete submission text file 0001437749-24-035616.txt   327894

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20241115.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20241115_def.xml EX-101.DEF 10354
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20241115_lab.xml EX-101.LAB 13837
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20241115_pre.xml EX-101.PRE 10349
17 EXTRACTED XBRL INSTANCE DOCUMENT pbla20241115_8k_htm.xml XML 2552
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 241471715
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)